AKIGAI

About AKIGAI

AKIGAI will disrupt the field of neuropathic pain (NP) by 2027.
With 4 layers to protect our EGFR inhibitor (EGFR-I) in the market, AKIGAI will reposition EGFR-Is, well known cancer drugs, for the treatment of NP.
Founders are oncologists, who serendipitously observed dramatic NP relief by EGFR-Is in the clinics. We have rarely witnessed such dramatic and meaningful drug effects as by ...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Norway
  • On CPHI since:
    2024
  • Employees:
    1 - 24
Company types
Other
Start-up
Primary activities
Pharmaceutical Company (generic finished products)
Contact info
Show contact info Hide contact info

AKIGAI Resources (1)

  • First look at the Start-Up companies at CPHI North America

    News First look at the Start-Up companies at CPHI North America

    In the following infographic, the first five Start-Up companies that are exhibiting at the brand new Start-Up Market at CPHI North America this May, are showcased. Hear from the Start-Ups themselves on what they are most looking forward to at the show. 

    13 Mar 2024